glp-1 agonists in development GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction Frontiers | GLP−1 receptor agonists

If they wish, RxSS can facilitate approval from their prescriber

10.2337/dcS15-3024 111 MarfellaR.BarbieriM.GrellaR.RizzoM

INTERHEART Study Investigators

New developments include orally administered GLP1RA, unimolecular glucagon receptor (GCGR)-GLP1R coagonists like survodutide, and GCGR- Gastric Inhibitory Polypeptide Receptor (GIPR)-GLP1R triagonists like retatrutide

Insulin has the advantage of being effective where other agents may not be and should be considered as part of any combination regimen when hyperglycemia is severe, especially if symptoms are present or any catabolic features (weight loss, ketosis) are present

DieboldSMoellmannJKahlesFHaj-YehiaELiehnEANickelAet alMyocardial infarction is sufficient to increase GLP-1 secretion, leading to improved left ventricular contractility and mitochondrial respiratory capacity